ALT-801 (Altor BioScience) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This ALT-801 (Altor BioScience) Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 3 August 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether ALT-801 (Altor BioScience) can convert its Fusion protein profile and IL-2R x p53 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | ALT-801 (Altor BioScience) (query alias: ALT-801 (Altor BioScience)) |
|---|---|
| Modality / target | Fusion protein; IL-2R x p53; IL-2R antagonists, p53 inhibitors |
| Highest global status | Phase 2 |
| Originator | Altor BioScience Corp. |
| Active developers | The University of Texas MD Anderson Cancer Center, National Cancer Institute |
The MCP disease footprint includes Bladder Cancer, Multiple Myeloma, Acute Myeloid Leukemia. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT05295875 | Phase 2 | Completed | 391 | Relative change from baseline in body weight percentage |
| NCT05989711 | Phase 2 | Completed | 212 | Proportion of subjects achieving NASH resolution (NAFLD activity score [NAS], ballooning = 0; lobular inflammation = 0, 1) with at least a 2-point reduction in NAS without worsening of fibrosis |
| NCT07009860 | Phase 2 | Recruiting | 100 | Relative (%) change in liver stiffness by VCTE compared to baseline at Week 24 |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Pemvidutide Treatment Yields Significant Reductions in Non- Invasive Tests of Liver Fibrosis and AI-Based Digital Pathology: Results from the Pemvidutide Phase 2b IMPACT Trial
Phase 2; n=212; evaluation: Positive. Reported fields: Advanced fibrosis(60% relative reduction) = 27.0 % ; Advanced fibrosis(60% relative reduction): P-Value = 0.0063; Advanced fibrosis(60% relative reduction) = 11.0 %
A Phase 2b, Multicenter, Randomized, Placebo-Controlled Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis: The IMPACT Trial
Phase 2; n=212; evaluation: Positive. Reported fields: Fibrosis improvement without worsening of MASH = 36.0 % ; Fibrosis improvement without worsening of MASH = 33.0 % ; Fibrosis improvement without worsening of MASH = 28.0 %
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial
Phase 2; n=212; evaluation: Positive. Reported fields: ELF(at week 48,mean reduction from baseline) = -0.58 Point ; ELF(at week 48,mean reduction from baseline) = -0.49 Point ; ELF(at week 48,mean reduction from baseline) = +0.16 Point
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
ALT-801 (Altor BioScience) addresses Bladder Cancer, Multiple Myeloma, Acute Myeloid Leukemia. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Fusion protein—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2019-07-08 | Spitfire and Mederis Diabetes enter into an amended and restated license agreement | Preclinical | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 3 August 2026. Counts and status fields may change as source records update.
